Jazz Pharmaceuticals PLC (JAZZ)

168.65 +2.88  +1.74% NASDAQ Jan 22, 20:00 USD
View Full Chart
Price Chart
View All JAZZ News

News

View All Events

Events

Date Type Description
02/25/2021 Earnings Jazz Pharmaceuticals PLC Fourth Quarter Earnings for 2020 Release
02/25/2021 16:30 EST Misc Jazz Pharmaceuticals PLC Fourth Quarter Earnings Conference Call for 2020
11/02/2020 Earnings Jazz Pharmaceuticals PLC Third Quarter Earnings Result for 2020
11/02/2020 16:30 EST Misc Jazz Pharmaceuticals PLC Third Quarter Earnings Conference Call for 2020
08/04/2020 16:30 EDT Misc Jazz Pharmaceuticals PLC Second Quarter Earnings Conference Call for 2020
08/04/2020 Earnings Jazz Pharmaceuticals PLC Second Quarter Earnings Result for 2020
07/30/2020 Misc Jazz Pharmaceuticals PLC Annual General Meeting for 2019
05/05/2020 16:30 EDT Misc Jazz Pharmaceuticals PLC First Quarter Earnings Conference Call for 2020
05/05/2020 Earnings Jazz Pharmaceuticals PLC First Quarter Earnings Result for 2020
02/25/2020 16:30 EST Misc Jazz Pharmaceuticals PLC Fourth Quarter Earnings Conference Call for 2019
View All Performance Charts

Total Returns Comparison

Ratings & Reports

Advertisement
Edit

Profile

  • URL: http://www.jazzpharmaceuticals.com
  • Investor Relations URL: http://investor.jazzpharma.com/phoenix.zhtml?c=210227&p=irol-irhome
  • HQ State/Province: N/A
  • Sector: Healthcare
  • Industry: Biotechnology
  • Equity Style: Mid Cap/Value
  • Next Earnings Release: Feb. 25, 2021
  • Last Earnings Release: Nov. 02, 2020
  • Next Ex-Dividend Date: N/A
  • Last Ex-Dividend Date: N/A
  • Description: Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and indications in neuroscience and hematology-oncology. Jazz's product portfolio includes its lead drug, Xyrem, for narcolepsy, Sunosi for improving wakefulness in patients with excessive daytime sleepiness, Defitelio for severe veno-occlusive disease after stem cell transplant, Vyxeos for acute myeloid leukemia, and Zepzelca for small cell lung cancer.

Top Fund Holders

Symbol Name Weighting
XPH SPDR® S&P Pharmaceuticals ETF 4.66%
PPH VanEck Vectors Pharmaceutical ETF 3.72%
IHE iShares US Pharmaceuticals ETF 3.27%
PJP Invesco Dynamic Pharmaceuticals ETF 2.97%
AASCX Thrivent Mid Cap Stock A 2.37%
RBF1542 RBC U.S. Mid-Cap Value Equity Fund D (USD) 2.35%
HNTVX Heartland Value Institutional 2.10%
FIDFX Fidelity Advisor® Mid Cap Value Z 1.86%
IBB iShares Nasdaq Biotechnology ETF 0.72%
MSCGX Mercer US Small/Mid Cap Equity Y3 0.59%
VISVX Vanguard Small Cap Value Index Inv 0.34%
VBR Vanguard Small-Cap Value ETF 0.34%

Comparables

Edit
Advertisement

{{root.upsell.info.feature_headline}}.

{{root.upsell.info.feature_description}}

Please note that this feature is only available as an add-on to YCharts subscriptions.


Please note that this feature requires full activation of your account and is not permitted during the free trial period.

Start My Free Trial {{root.upsell.info.call_to_action}} No credit card required.

Already a subscriber? Sign in.